Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
JCL roundtable: PCSK9 inhibitors in clinical practice.
Brown WV, Moriarty PM, McKenney JM. Brown WV, et al. Among authors: moriarty pm. J Clin Lipidol. 2016 Jan-Feb;10(1):5-14. doi: 10.1016/j.jacl.2015.12.004. Epub 2015 Dec 12. J Clin Lipidol. 2016. PMID: 26892118
JCL Roundtable: Should we treat elevations in Lp(a)?
Brown WV, Moriarty PM, Remaley AT, Tsimikas S. Brown WV, et al. Among authors: moriarty pm. J Clin Lipidol. 2016 Mar-Apr;10(2):215-24. doi: 10.1016/j.jacl.2016.02.012. Epub 2016 Mar 5. J Clin Lipidol. 2016. PMID: 27055952
The use of lipopheresis in the practice of clinical lipidology.
Brown WV, Brook R, Hemphill LC, Moriarty PM. Brown WV, et al. Among authors: moriarty pm. J Clin Lipidol. 2012 Mar-Apr;6(2):98-104. doi: 10.1016/j.jacl.2011.12.003. Epub 2011 Dec 22. J Clin Lipidol. 2012. PMID: 22385541 No abstract available.
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S, Ali S, Manvelian G, Pordy R. Moriarty PM, et al. J Clin Lipidol. 2020 Jan-Feb;14(1):88-97.e2. doi: 10.1016/j.jacl.2020.01.001. Epub 2020 Jan 13. J Clin Lipidol. 2020. PMID: 32192644 Free article. Clinical Trial.
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA; ODYSSEY ALTERNATIVE Investigators. Moriarty PM, et al. J Clin Lipidol. 2015 Nov-Dec;9(6):758-769. doi: 10.1016/j.jacl.2015.08.006. Epub 2015 Aug 29. J Clin Lipidol. 2015. PMID: 26687696 Free article. Clinical Trial.
JCL roundtable-Lipoprotein(a): The emerging risk factor.
Marcovina SM, Moriarty PM, Koschinsky ML, Guyton JR. Marcovina SM, et al. Among authors: moriarty pm. J Clin Lipidol. 2018 Nov-Dec;12(6):1335-1345. doi: 10.1016/j.jacl.2018.11.003. J Clin Lipidol. 2018. PMID: 30527801
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE. Goldberg AC, et al. Among authors: moriarty pm. J Clin Lipidol. 2011 May-Jun;5(3):133-140. doi: 10.1016/j.jacl.2011.03.001. Epub 2011 Mar 11. J Clin Lipidol. 2011. PMID: 21600517
Statin-associated muscle symptoms-Managing the highly intolerant.
Backes JM, Ruisinger JF, Gibson CA, Moriarty PM. Backes JM, et al. Among authors: moriarty pm. J Clin Lipidol. 2017 Jan-Feb;11(1):24-33. doi: 10.1016/j.jacl.2017.01.006. Epub 2017 Jan 18. J Clin Lipidol. 2017. PMID: 28391891 Review.
143 results